List of Biologics Companies in Colorado - 19

Allander biotechnologies is a biotech company at the R&D stage focusing on drug development for unmet medical needs in tissue regeneration.

Bolder BioTechnology has a diversified pipeline of proprietary, long-acting human protein pharmaceuticals that include potential treatments for hematological and endocrine disorders, cancer supportive care, and orphan genetic diseases.

Cerapedics is a global, commercial-stage orthopedics company that aspires to redefine the standard of care for bone repair by healing bones faster and at higher rates, without compromising safety, so that patients can live their healthiest lives. Bone grafts, including Cerapedics’ products, are used in over four million annual spine, orthopedics, trauma and interventional procedures world-wide. Cerapedics’ product, i-FACTOR®, is FDA approved for single-level cervical spinal fusions in the United States. Cerapedics’ next-generation product is currently being evaluated for use in lumbar interbody fusion through ASPIRE, a pivotal IDE study, and has been granted a Breakthrough Device Designation by the FDA. Cerapedics is headquartered in Westminster, CO.

cGMPnow accelerates Gene & Cell Therapy products to patients by providing GMP Manufacturing & QC Laboratory Equipment, Automation & Controls (IT/OT), Commissioning & Qualification, and Procurement services using project-dedicated expert resources.

Colorado Serum Company specializesin manufacturingUSDA-licensed large animal biologicals, Colorado Serum Company’s product line includes Serum Antibodies, Bacterins, Toxoids, Bacterin-Toxoids, Antitoxins, Spore, and Modified Live vaccines.

Colorado State University is a Higher Education institution that offers a variety of academic programs and conducts research in various fields.

DMC Biotechnologies has developed its Dynamic Metabolic Control technology, a novel, low cost technology for rapid engineering of robust microbial hosts that enables the production of a broad diversity of specialty chemicals, flavors, fragrances, neutracueticals, natural products, pharmaceuticals, and APIs.

GID Group’s SVF-2 device and therapy, pending FDA approval, gives providers and patients a major development in cellular medicine to help treat osteoarthritis pain and to delay or provide an alternative to total knee replacement surgery. GID’s technology harvests, isolate and reimplants the right type and combination of one’s own healing cells. Our first FDA-approved pivotal clinical study, a closely watched rigorous trial, had no serious adverse events and showed significant improvements in pain and function. The FDA has granted conditional approval for a second final pivotal clinical trial. Cellular therapy addresses an unmet need in 14 million people living with osteoarthritis of the knee, offering a less time consuming, painful and costly treatment for everyone that requires no joint surgery and no drugs for osteoarthritis pain. Help relieve the $200 billion burden of osteoarthritis management on our healthcare system. Heal intelligently.

Greffex™ is a privately held, multi-national company, headquartered in Aurora, Colorado. Established in 1999, Greffex has developed a novel genetic platform for the development and production of vaccines. Our proprietary GREVAX™ Universal Platform delivers vaccines in a faster, more affordable and more efficient manner. Once a pathogen has been identified, Greffex's team designs and produces a GREVAX™ vaccine in as little as 4 weeks. The state-of-the-art flexibility of the GREVAX™ Universal Platform makes it the ideal delivery vehicle for vaccines against a wide variety of infectious disease, including but not limited to Pandemic Influenza strains, Anthrax and Dengue Fever, as well as Malaria, Hepatitis C, Respiratory Syncytial Virus (RSV), Ebola, HPV, Plague, Tuberculosis and a host of other vaccine candidates.

MenoGeniX is a privately-held, clinical stage biopharmaceutical company, dedicated to researching and developing a novel potential treatment for women suffering from hot flashes and related vasomotor symptoms of menopause.

Neurexis is developing an optimized peptide with demonstrated efficacy and safety in small and large animal models of global cerebral ischemia.

At OncoVerity, we're not just developing a new treatment—we're doing something truly unique and meaningful. We're establishing a disruptive model using cutting-edge technology to advance cancer therapies. Our mission is to quickly advance therapies that turn hope into reality for patients, their families, and caregivers.   One of the things that sets OncoVerity apart is our approach. We are knocking down traditional barriers between academia and industry by building a team that bridges both worlds. We believe that cutting-edge technology is essential, but it is only one piece of the puzzle.   The true power behind our vision lies in: The brilliance of our people: Your entrepreneurship, ingenuity, drive, and passion are what will fuel our success. The richness of our diversity: A variety of perspectives and backgrounds is essential for groundbreaking solutions. The strength of our collaboration: We are stronger together, and teamwork is at the heart of everything we do.

RheumaGen is the only cell and gene therapy company editing the HLA gene to cure autoimmune diseases at their source.

Sudhin Biopharma Co. is a biotechnology company developing efficient continuous biological manufacturing processes for therapeutic biologicals, sweet proteins, cell therapies and biological roducts.

Headquartered in Lakewood, Colorado, Terumo Blood and Cell Technologies provides blood component, therapeutic apheresis and cellular technologies serving customers in more than 130 countries.

For patients and doctors battling chronic resistant infections, Validus Cellular Therapeutics is developing VCT-101, a novel preclinical stage anti-infective therapy unlike current small molecule antibiotics which are susceptible to resistance and are limited accessing infections. VCT-101 is a cell therapy to be given with standard of care antibiotic regimens to successfully treat of chronic infections through direct bacterial killing and immune system boosting mechanisms.

Vivaldi Biosciences is developing vaccines for protection against epidemic and pandemic viral respiratory diseases using its Delta NS1 vector and innovative cell-based production technologies. Vivaldi’s DeltaFLU universal influenza vaccine is in Phase 2 clinical development. Its Delta-19 universal influenza/Covid-19 vaccine will enter clinical trials in 2021. Delta NS1 is a versatile and robust technology platform for self-adjuvanting vaccines administered by nasal spray. Delta NS1 is a replication-deficient vaccine vector based on a genetically modified, safely attenuated influenza virus strain. Delta NS1-based vaccines have the unique ability to rapidly induce interferon, generating protection against circulating viruses entering the nasal passages, and activating systemic antibody and cell-based protective immunity.

ZimVie is a global leader in dental implants and spine innovations. Advancing clinical technology foundational to restoring daily life.